About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The group of Clinical Neuroimmunology - Centre d'Esclerosi Múltiple de Catalunya (Cemcat) at the Vall d'Hebron Institut de Recerca (VHIR) is a multidisciplinary group dedicated to clinical assistance, physical and cognitive rehabilitation, and clinical and basic research on multiple sclerosis (MS). Cemcat is a national but also an international reference center in the clinical assistance of MS patients. The research performed in the group is divided and further combined in clinical and basic research. In addition, basic research has a marked translational character since the ultimate goal of the group is to improve the quality of life of patients suffering from MS, through in-depth knowledge of the pathogenic mechanisms of the disease and the development of new and more effective therapeutic approaches.
PMID: 35512501 Journal: Multiple Sclerosis and Related Disorders Year: 2022 Reference: Mult Scler Relat Disord. 2022 Jul;63:103805. doi: 10.1016/j.msard.2022.103805. Epub 2022 Apr 12. Impact factor: 4.339 Publication type: Paper in international publication Authors: Costa-Frossard, Lucienne, Gonzalez Platas, Montserrat, Pascual, Lamberto Landete, Llaneza-Gonzalez, Miguel, Gines, Maria Luisa Martinez, Matias-Guiu, Jorge, Meca-Lallana, Jose E, Bilbao, Mar Mendibe, Sempere, Angel Perez, Romero-Pinel, Lucia et al. DOI: 10.1016/j.msard.2022.103805
PMID: 35504675 Journal: Radiologia Year: 2022 Reference: Radiologia. 2022 Mar-Apr;64(2):103-109. doi: 10.1016/j.rxeng.2020.04.009. Impact factor: 0 Publication type: Paper in international publication Authors: Remollo, S, Lopez-Rueda, A, Vargas, A, Pinana, C, Chirife, O, Werner, M, Aja, L, Tomasello, Y A et al. DOI: 10.1016/j.rxeng.2020.04.009
PMID: 35491662 Journal: INTERVENTIONAL NEURORADIOLOGY Year: 2022 Reference: Interv Neuroradiol. 2022 May 2:15910199221095798. doi: 10.1177/15910199221095798. Impact factor: 1.61 Publication type: Paper in international publication Authors: Requena, Manuel, Pinana, Carlos, Olive-Gadea, Marta, Hernandez, David, Boned, Sandra, De Dios, Marta, Rodrigo, Marc, Rivera, Eila, Muchada, Marian, Cuevas, Jose Luis et al. DOI: 10.1177/15910199221095798
PMID: 35487685 Journal: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY Year: 2022 Reference: J Neurol Neurosurg Psychiatry. 2022 Apr 29. pii: jnnp-2022-329020. doi: 10.1136/jnnp-2022-329020. Impact factor: 10.283 Publication type: Paper in international publication Authors: Comabella, Manuel, Sastre-Garriga, Jaume, Carbonell-Mirabent, Pere, Fissolo, Nicolas, Tur, Carmen, Malhotra, Sunny, Pareto, Deborah, Aymerich, Francesc X, Rio, Jordi, Rovira, Alex et al. DOI: 10.1136/jnnp-2022-329020
PMID: 32176761 Journal: Journal of Gastrointestinal and Liver Diseases Year: 2020 Reference: J Gastrointestin Liver Dis. 2020 Mar 13;29(1):65-68. doi: 10.15403/jgld-806. Impact factor: 2.351 Publication type: Paper in international publication Authors: Pribic, Teodora, Lopez, Quiro, Lucas, Eduardo, Livovsky, Dan M, Rovira, Alex, Accarino, Anna, Azpiroz, Fernando, Pareto, Deborah et al. DOI: 10.15403/jgld-806
PMID: 32139431 Journal: AMERICAN JOURNAL OF NEURORADIOLOGY Year: 2020 Reference: AJNR Am J Neuroradiol. 2020 Mar;41(3):461-463. doi: 10.3174/ajnr.A6481. Epub 2020 Mar 5. Impact factor: 3.381 Publication type: Paper in international publication Authors: Pareto, D, Garcia-Vidal, A, Alberich, M, Auger, C, Montalban, X, Tintore, M, Sastre-Garriga, J, Rovira, A et al. DOI: 10.3174/ajnr.A6481
PMID: 31918065 Journal: NeuroImage-Clinical Year: 2020 Reference: Neuroimage Clin. 2020;25:102149. doi: 10.1016/j.nicl.2019.102149. Epub 2019 Dec 28. Impact factor: 4.35 Publication type: Paper in international publication Authors: Salem, Mostafa, Valverde, Sergi, Cabezas, Mariano, Pareto, Deborah, Oliver, Arnau, Salvi, Joaquim, Rovira, Alex, Llado, Xavier et al. DOI: 10.1016/j.nicl.2019.102149
PMID: 32094485 Journal: Nature Reviews Neurology Year: 2020 Reference: Nat Rev Neurol. 2020 Mar;16(3):171-182. doi: 10.1038/s41582-020-0314-x. Epub 2020 Feb 24. Impact factor: 27 Publication type: Review in international publication Authors: Palace, Jackie, Sastre-Garriga, Jaume, Pareto, Deborah, Battaglini, Marco, Rocca, Maria A, Ciccarelli, Olga, Enzinger, Christian, Wuerfel, Jens, Sormani, Maria P, Barkhof, Frederik et al. DOI: 10.1038/s41582-020-0314-x
In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.
Dr. Carmen Espejo and Dr. Georgina Arrambide, researchers at Cemcat and Vall d'Hebron Research Institute, are the first authors of the article.
The research findings propose to modify the McDonald 2017 criteria, only in those in whom diagnosis using the current criteria is not possible.
Simoa HD1 equipment
We are looking for 100 healthy volunteers aged 18 or over to participate in a project where the usefulness of biomarkers in serum will be evaluated to predict the prognosis of the disease and the response to treatments.
